Dual inhibition of HSF1 and DYRK2 impedes cancer progression. Issue 1 (30th January 2023)

• Record Type: Journal Article
• Authors: Tandon, Vasudha; Moreno, Rita; Allmeroth, Kira; Quinn, Jean; Wiley, Sandra E.; Nicely, Lynden G.; Denzel, Martin S.; Edwards, Joanne; de la Vega, Laureano; Banerjee, Sourav
• Is Part Of: Bioscience reports. Volume 43:Issue 1(2023)
• Publication Date: 2023-01-30
• Subjects: inhibition -- myeloma -- proteasomes -- stress kinases; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20222102
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a tractable strategy to target cancers sensitive to proteotoxic stress; however, the development of HSF1 inhibitors remains in its infancy. Importantly, multiple other kinases have been shown to redundantly activate HSF1 that promoted ideas to directly target HSF1. The eventual development of direct HSF1 inhibitor KRIBB11 suggests that the transcription factor is indeed a druggable target. The current study establishes that concurrent targeting of HSF1 and DYRK2 can indeed impede cancer by inducing apoptosis faster than individual targetting. Furthermore, targeting the DYRK2-HSF1 axis induces death in proteasome inhibitor-resistant cells and reduces triple-negative breast cancer (TNBC) burden in ectopic and orthotopic xenograft models. Together the data indicate that cotargeting of kinase DYRK2 and its substrate HSF1 could prove to be a beneficial strategy in perturbing neoplastic malignancies.